Mode
Text Size
Log in / Sign up

HPV detection is more frequent in prostate cancer cases with an OR of 3.01Higher rates of HPV found in men with prostate cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher HPV detection in prostate cancer cases does not support specific prevention recommendations.

This meta-analysis synthesized 57 primary observational reports to evaluate the association between prostate cancer and various risk factors, including sexual behavior-related exposures, STI history, and viral markers such as HPV and Trichomonas vaginalis. The analysis included a pooled model of 13 studies specifically for HPV.

The primary finding was that tissue- or PCR-based HPV detection was more frequent among prostate cancer cases, with an OR of 3.01 (95% CI 1.97-4.61; I2=36.2%; prediction interval 1.15-7.91). While HPV16 and HPV18 subtypes were elevated, HPV serology showed no clear association. Results for Trichomonas vaginalis serology, history-based STI exposure, and sexual-behavior exposures were reported as imprecise, heterogeneous, or too heterogeneous for pooling.

The authors noted several limitations, including risk of bias, limited temporal clarity, sampling and comparator differences, and general methodological limitations. Due to the very low certainty across all evaluated exposure domains, the findings do not support clinical recommendations for prostate cancer prevention based on HPV vaccination, STI screening, or sexual-behavior modification.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the role of viral markers and sexual behavior in prostate cancer. While previous evidence highlights the role of biomarker-driven strategies and genomic classifiers for risk stratification, this study finds that while HPV detection is more frequent in prostate cancer cases (OR 3.01), the evidence is of very low certainty and does not support specific prevention recommendations based on vaccination or screening.

Doctors are looking closely at the link between common viruses and prostate cancer. A large review of 57 reports found that men with prostate cancer were much more likely to have detectable HPV, specifically the high-risk types 16 and 18. This finding suggests a strong connection between the virus and the cancer.

However, the evidence is not perfect. Because the data came from many different studies with different methods, the certainty of these results is very low. While the link to HPV is clear in the data, it does not mean the virus causes the cancer or that current medical habits need to change.

For now, these findings do not mean that doctors should change how they screen for infections or recommend vaccines for prostate cancer prevention. The study highlights a strong association, but it does not prove that changing sexual behavior or getting a vaccine will lower cancer risk.

What this means for you:
Men with prostate cancer have higher rates of HPV, but this does not currently change cancer prevention advice.

Common questions

Does having HPV increase the risk of prostate cancer?

The study found that men with prostate cancer were much more likely to have detectable HPV, including types 16 and 18. However, the researchers noted that these results do not prove that the virus causes the cancer, and the overall certainty of the data is very low.

Should I get an HPV vaccine to prevent prostate cancer?

The findings in this study do not support making changes to current medical recommendations. This means that HPV vaccination, STI screening, or changes in sexual behavior are not currently recommended as ways to prevent prostate cancer based on this data.

What other infections were linked to prostate cancer?

The study looked at other factors like Trichomonas vaginalis and past history of STIs. However, the results for these specific infections were inconsistent or unclear, so they do not provide a clear link to prostate cancer at this time.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BackgroundSexual behavior, sexually transmitted infections (STIs), and viral markers have been investigated in relation to prostate cancer, but heterogeneous exposure definitions and ascertainment methods complicate interpretation. We synthesized observational evidence separately across biologically and methodologically distinct exposure domains.MethodsWe followed PRISMA 2020 and searched PubMed/MEDLINE, Embase.com, and Web of Science Core Collection from inception through 27 May 2026. Eligible studies were comparative observational studies evaluating sexual behavior-related exposures, STI history or serology, or viral markers in relation to prostate cancer. Random-effects meta-analysis was performed for sufficiently comparable estimates. Risk of bias was assessed using Newcastle-Ottawa Scale domains, supplemented by design-specific epidemiological considerations. GRADE was used as a post-registration evidence-certainty assessment.ResultsOf 121 reports assessed for eligibility, 57 primary observational reports were included after final eligibility reconciliation. Twenty-five reports entered at least one pooled model and three additional reports appeared only in descriptive forest plots. For tissue- or PCR-based HPV detection, the observed pooled association was OR 3.01 (95% CI 1.97-4.61; I²=36.2%; prediction interval 1.15-7.91; 13 studies). HPV16 and HPV18 tissue/PCR subtype estimates were also elevated, whereas HPV serology showed no clear association. Estimates for Trichomonas vaginalis serology and history-based STI exposure were imprecise or heterogeneous, and sexual-behavior exposures were too heterogeneous for pooling. Certainty was very low across all evaluated exposure domains.ConclusionsTissue- or PCR-based HPV detection was more frequent among prostate cancer cases in the available comparative studies, but the evidence is very uncertain because of risk of bias, limited temporal clarity, sampling and comparator differences, and other methodological limitations. These findings should not be interpreted as establishing an etiologic or causal effect and do not support prostate-cancer prevention recommendations based on HPV vaccination, STI screening, or sexual-behavior modification.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1334823, identified: CRD420261334823.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.